Mounjaro Alternatives: What Costs Less and What You Give Up

The cheapest real alternative to Mounjaro is usually Mounjaro’s own molecule under another name. Zepbound is tirzepatide too, and as of October 2026 Lilly sells it for $299 to $449 a month in cash, against $499 for Mounjaro at every dose.^[3][5][6] It carries a weight label, not a diabetes one, so it fits only if you qualify on weight.^[2] If you need a drug for type 2 diabetes alone, Ozempic ($349 a month at most doses) and Trulicity ($389) cost less,^[18][20] and lower blood sugar and weight less than Mounjaro did in head-to-head trials.^[10][11] Generic liraglutide is the cheapest GLP‑1, about $184 for a month at the top dose, but it is a daily shot.^[21] Compounded tirzepatide is no longer a shortage stopgap, and FDA has proposed shutting the outsourcing route for it.^[7][8]

Start with why Mounjaro is out

“Alternative” means three different things depending on the problem. If Mounjaro works but the price or the plan is the obstacle, the best answer is often the same molecule bought another way. If your insurer will pay for some diabetes drugs but not this one, the answer is whichever drug on its formulary comes closest. If Mounjaro itself did not suit you, because of side effects or because it did not work, the answer may sit outside the GLP‑1 class altogether. The table below sorts the options that way.

Mounjaro’s list price, the wholesale figure before any discount, is $1,112.16 a month.^[4] Almost nobody pays it. What follows is what each option costs and what you give up for it.

Same molecule: Zepbound and Mounjaro self-pay

Mounjaro and Zepbound contain the same drug, tirzepatide, made by the same company. Mounjaro’s label covers blood-sugar control in type 2 diabetes, for grown-ups and for children 10 and older. Since August 2026 it also covers cutting the odds of a major cardiovascular event (heart attack, stroke or cardiovascular death) for diabetic patients whose risk is high.^[1] Zepbound’s label is about weight: grown-ups with obesity, or those who are overweight and carry at least one weight-linked health problem. It is also cleared for moderate to severe sleep apnea when obesity is present.^[2] Our Mounjaro vs Zepbound comparison sets the two labels side by side.

The prices do not match. Lilly charges self-pay Mounjaro buyers a flat $499 whatever the strength, and TrumpRx shows the same number.^[3][4] Zepbound from LillyDirect, as a multi-dose KwikPen or single-dose vials, is cheaper at every step, as long as each refill lands within 45 days of the one before.^[5][6] Let that window lapse and the KwikPen goes back to its regular price, the last column below.^[5] Lilly calls 2.5 mg a starting dose rather than a maintenance one, so the lowest Zepbound price covers only the first month.^[5]

Zepbound has been studied in people with diabetes. One trial on its label ran 72 weeks and enrolled 938 people who had both type 2 diabetes and a BMI no lower than 27. Weight fell 12.8% on 10 mg and 14.7% on 15 mg, against 3.2% on placebo.^[2] Low blood sugar was more common on the drug, 4.2% against 1.3%, and the risk rises with a sulfonylurea. The catch is the indication. A prescriber can write Zepbound for weight in someone who also has diabetes, but not for diabetes alone, and an insurer that excludes weight-loss drugs will not cover it.

• Commercial plan covers Mounjaro: Lilly’s savings card brings it to as little as $25, capped at $1,950 a year. Nothing on this page beats that.^[3]
• Commercial plan refuses Mounjaro: the same card sets the price at $499 for a 28-day fill, capped at $8,411 a year. Zepbound self-pay is cheaper if you qualify for it. Both cards end December 31, 2026.^[3]
• Medicare: Lilly’s cards exclude government beneficiaries.^[3] Medicare’s $50 GLP‑1 Bridge does not cover anyone with type 2 diabetes; it points them back to their Part D plan, which may cover Mounjaro for diabetes.^[27]
• No insurance: compare Mounjaro at $499 with Zepbound at $299 to $449. For how TrumpRx fits in, see what TrumpRx lists for GLP-1 drugs.

Do not take both. Zepbound’s label advises against using it with any other tirzepatide product or any GLP‑1 drug.^[2]

Compounded tirzepatide is not the shortage-era option it was

During the shortage that began in 2022, pharmacies could legally make copies of tirzepatide. FDA has since determined the shortage is resolved. Its grace period for state-licensed pharmacies has ended, and the one for outsourcing facilities ran out in March 2025. FDA’s position is that tirzepatide is on neither the shortage list nor the outsourcing facilities’ bulk list.^[7] A pharmacy may still make an altered version for one named patient, if the alteration matters clinically for that person. For plain copies of the approved drug, FDA says it will not act only when a pharmacy fills four or fewer prescriptions a month.^[7]

In May 2026 FDA proposed to keep tirzepatide, semaglutide and liraglutide off the bulk list for outsourcing facilities for good.^[8] No final decision had been published as of October 2026. FDA also points out that compounded drugs are not FDA-approved, and that it has found compounded tirzepatide whose label named a pharmacy that never made it.^[9] The compounded market still exists, and its prices are tracked in what a GLP-1 costs without insurance. Whether it is a safe swap is the subject of is compounded tirzepatide safe. It is not Mounjaro, and no trial of Mounjaro measured it.

If you do look at that market, the sellers differ in ways the headline figure hides. Form is one: Curex and AZ Health sell compounded tirzepatide as a dissolving tablet as well as a shot, and Found Youth also sells it as sublingual drops. The dose ladder is another. Ivologist charges one maintenance price at every dose once its starter phase ends, while TeleDocs360 charges more for tirzepatide above the 10 mg dose.

Then come the terms. Fitness RX asks for three months on its advertised plans, StaveMD renews every four weeks, and Nucore Health shows the billing term behind its figures only after intake. HealthRX takes payment before the intake and refunds a decline in full. If you want the brand to stay on the table, PlushCare is a virtual primary-care practice whose clinicians can prescribe Mounjaro and Zepbound as well as compounded versions.

Other GLP-1 drugs for type 2 diabetes

If the drug has to be for diabetes, four GLP‑1 options remain: Ozempic, oral semaglutide (sold as Rybelsus and as Ozempic tablets), Trulicity and liraglutide (Victoza and its generics). All four lower blood sugar, and each label also carries a heart-outcome indication.^{[14][15][16][17]} What none has is Mounjaro’s size of effect. No single trial compared all of them, but a chain of head-to-head trials links each to the next.

SURPASS-2 took 1,879 people already on metformin and assigned each by chance to one of three tirzepatide strengths (5, 10 and 15 mg) or to semaglutide 1 mg, the Ozempic dose sold at the time. Every tirzepatide dose lowered HbA1c more than semaglutide, and the weight gap at the top dose was 5.5 kg.^[1][10] The trial was open-label and funded by Lilly, and it did not test Ozempic’s later 2 mg dose. The detail is on the SURPASS-2 trial page.

Semaglutide 1 mg in turn beat Trulicity 1.5 mg in SUSTAIN 7, by 0.4 points of HbA1c and 3.5 kg of weight.^[11] Oral semaglutide 14 mg matched liraglutide 1.8 mg on HbA1c in PIONEER 4 and took off 1.2 kg more (the trial’s estimated difference; the rounded averages in the table differ by 1.3 kg).^[12] Read down the table and the order is plain: tirzepatide, then semaglutide, then dulaglutide and liraglutide. Moving off Mounjaro to any of them means accepting a smaller effect on both numbers. For the specific pairs, see Ozempic vs Mounjaro, Trulicity vs Mounjaro and Rybelsus vs Mounjaro.

Heart outcomes are closer. SURPASS-CVOT split 13,299 people by chance between tirzepatide and Trulicity; every one had type 2 diabetes and established heart disease. Trulicity was picked as the comparator because it had already been shown to cut cardiovascular events. The combined tally of heart attacks, strokes and cardiovascular deaths came to 12.2% of the tirzepatide group and 13.1% of the Trulicity group. That met the test for being no worse, but not the test for being better (hazard ratio 0.92, confidence interval 0.83 to 1.01).^[13] On heart protection, then, Trulicity is a like-for-like substitute in a way it is not on weight.

What each one costs

• Ozempic pen: someone new to NovoCare’s cash program gets two starter fills (0.25 or 0.5 mg) at $199 apiece, through December 31, 2026. From the third month the price is $349 for doses up to 1 mg and $499 for 2 mg.^[18]
• Ozempic tablets: a bottle of 30 runs $149 (1.5 mg), $199 (4 mg) or $299 (9 mg); the wholesale list price is $1,027.51. Government beneficiaries are excluded.^[19] They share a label with Rybelsus; the doses differ and are not interchangeable milligram for milligram.^[15]
• Trulicity: $389 a month at every strength through LillyDirect, against a $987.19 wholesale list price.^[20]
• Generic liraglutide: TrumpRx lists a pharmacy coupon price of $133.58 for a box of two pens and $184.41 for three.^[21] Each pen holds 18 mg, so at the top dose of 1.8 mg a day three pens last 30 days.^[17]

Liraglutide is the only GLP‑1 with generics on sale. FDA approved the first, from Hikma, in December 2024, and several more have followed.^[22] There is no generic tirzepatide, dulaglutide or semaglutide (see which GLP-1 generics actually exist). Liraglutide is still on FDA’s shortage list. In October 2026 the generic presentations were listed as available and brand Victoza as limited.^[23] It is also a daily injection, with one of the smallest weight effects in the table above.

Switching from Mounjaro to any of these means starting the new drug’s own dose ladder, usually from the bottom. No published table converts a tirzepatide dose to a semaglutide or dulaglutide dose. Switching between GLP-1 drugs covers what to expect in the gap.

Outside the GLP-1 class: SGLT2 inhibitors and metformin

If GLP‑1 drugs are the problem, for example nausea you could not get past, the diabetes options outside the class are older and cheaper, and much weaker for weight.

SGLT2 inhibitors such as Jardiance and Farxiga make the kidneys pass sugar into the urine. In Jardiance’s 24-week trial as a stand-alone drug, HbA1c fell 0.7 to 0.8 points and weight 2.8% to 3.2%, against 0.4% on placebo.^[24] Jardiance also carries heart failure and kidney indications.^[24] FDA approved generic versions of Farxiga (dapagliflozin) from more than a dozen manufacturers in April 2026.^[25] SGLT2s are often added to a GLP‑1 rather than used instead of one; see taking an SGLT2 inhibitor and a GLP-1 together.

Metformin is the usual first diabetes drug and has been generic for decades. In the 29-week placebo trial on its label, run in people with type 2 diabetes who also had obesity, HbA1c fell 1.4 points against a 0.4-point rise on placebo. Weight barely moved: down 1.4 lb on metformin and 2.4 lb on placebo.^[26] It controls sugar; it is not a weight drug. Everyone in SURPASS-2 was already taking it alongside the study drug.^[10] See metformin and a GLP-1 together.

When the problem is coverage, not the drug

A refused Mounjaro claim is often a formulary decision, not a final one. Plans commonly require you to try a cheaper preferred drug first, often metformin or a GLP‑1 they have a contract on, and then approve Mounjaro on a prior authorization or exception request. Before paying $499 a month, ask the plan which GLP‑1 it prefers and what documentation would get Mounjaro approved. GLP-1 prior authorization and appeals and how to get a GLP-1 covered go through the steps. If the preferred drug is Ozempic or Trulicity, the trade is the one in the trials above: a covered drug with a smaller effect, against $499 a month for the larger one.